Global consumer goods conglomerate Reckitt Benckiser Group announced last week a record $1.4 billion civil settlement with the federal government over sales and marketing of the opioid Suboxone. The settlement included what appears to be an unprecedented nonprosecution agreement that allows the company to deny any wrongdoing.

Brandon Garrett, a professor at Duke University School of Law, told Corporate Counsel the agreement was unusual. “It is typical for a corporation to admit, accept, and acknowledge responsibility for both acts set forth in a statement of facts and specific criminal law violations, in a nonprosecution agreement,” Garrett said.

Brandon L. Garrett, L. Neil Williams Professor of Law at Duke University School of Law. Brandon L. Garrett (Courtesy photo)

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]